DeCure for Hantavirus hemorrhagic fever with renal syndrome
DeCure's autonomous Nephrology AI scientist is researching a drug-repurposing hypothesis for hantavirus hemorrhagic fever with renal syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHantavirus hemorrhagic fever with renal syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hantavirus hemorrhagic fever with renal syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
CD8 subunit alpha (CD8A) — CD8A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 6-formyl-4-oxo-3,4-dihydropteridin-2-yldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7UMG · 2.4 Å · ligand N-(6-formyl-4-oxo-3,4-dihydropteridin-2-yl)acetamide (30W). Experimental structure, not a prediction.
What the evidence adds up to
In 2013, the first laboratory-confirmed cases of hantavirus infection from the Middle Anatolia Region of Turkey were reported, including the first documented co-infection of hantavirus and Crimean-Congo hemorrhagic fever virus in a single patient. That co-infected patient was tested for hantavirus only because the illness lasted longer than expected for Crimean-Congo hemorrhagic fever alone and because renal function was impaired. Diagnosis of Crimean-Congo hemorrhagic fever was confirmed by serological and molecular methods, and IgM and IgG antibodies for hantavirus were also positive. All three patients in this report were discharged after receiving supportive therapy only; no antiviral or specific drug treatment was described.
A 2012 case report describes a patient in South Korea with hemorrhagic fever with renal syndrome and coexisting hantavirus pulmonary syndrome, a combination rarely seen outside the Americas. The report does not provide any drug treatment or survival outcome beyond noting the presentation of both syndromes. A 2009 review states that the pathogenesis of hantavirus is not yet entirely clear, listing virus, virus receptor, cytokines, free radicals, specific CTL response, and HLA differences as possibly related factors, but offers no therapeutic intervention.
A 2019 study evaluated the activity of human serum albumin on selected hantavirus aptamers, focusing on diagnostic mechanisms rather than treatment. No drug, antiviral, or therapeutic candidate is tested or proposed in any of these abstracts. The evidence base for treating hantavirus hemorrhagic fever with renal syndrome remains limited to supportive care, with no controlled trial data, no repurposed drug tested in patients, and no validated animal model results reported here. What is still missing is any randomised clinical trial, any drug candidate with demonstrated human efficacy, and any clear patient stratification strategy for future studies.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Turkiye Klinikleri Journal of Medical Sciences · 2013 · 7 citations · open access
First Cases of Hemorrhagic Fever with Renal Syndrome from the Middle Anatolia Region of Turkey and the First Case of Hantavirus and Crimean-Congo Hemorrhagic Fever Virus Co-Infection in a Patient
AbstractThe first laboratory confirmed cases of hemorrhagic fever with renal syndrome caused by hantavirus infection in Turkey were published in 2009. We reported the first cases of hantavirus infection from the Middle Anatolia Region of Turkey as well as the first case of co-infection caused by hantavirus and Crimean-Congo hemorrhagic fever (CCHF) virus in a patient. The co-infected patient was tested for hantavirus infection because the duration of the illness lasted longer than expected for CCHF and renal function was impaired. Diagnosis of CCHF was confirmed with serological and molecular methods; in addition, IgM and IgG antibodies for hantavirus were positive. All three patients were discharged after they received supportive therapy.
Kidney Research and Clinical Practice · 2012 · 7 citations · open access
Hemorrhagic fever with renal syndrome and coexisting hantavirus pulmonary syndrome
AbstractHemorrhagic fever with renal syndrome (HFRS) is an acute viral disease with fever, hemorrhage and renal failure caused by hantavirus infection. Hantavirus induces HFRS or hantavirus pulmonary syndrome (HPS). HPS progression to a life-threatening pulmonary disease is found primarily in the USA and very rarely in South Korea. Here, we report a case of HFRS and coexisting HPS.
Research progress on the pathogenic mechanisms of hemorrhagic fever with renal syndrome
AbstractThe pathogenisis of hantavirus is not yet entirely clear. Virus, virus receptor, cytokines, free radi-cals, specific CTL response and HLA differences may be related to the pathogenesis. In this review, the research progress on the pathogenesis of hantavirus is reviewed.
Key words:
Hemorrhagic fever with renal syndrome; Hantavirus; Pathogenesis
Evaluation of HSA activity on selected hantavírus aptamers
AbstractHantaviruses are enzootic viruses that maintain persistent infections in their rodent hosts without apparent disease symptoms. The spillover of these viruses to humans can lead to serious illnesses as, hantavirus pulmonary syndrome and hemorrhagic fever with renal syndrome. In recent years, there has been an improved understanding of the epidemiology, pathogenesis, and natural history of these viruses following by the necessity to investigate a diagnostic mechanism.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
